Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30668575 | 1.00 | HDAC3 (0.38) | HDAC3HSD17B3PARP1RXFP1NOTUM | |
| Hydrochloric Acid SCHEMBL28318712 | 0.98 | HDAC3 (0.38) | HDAC3HSD17B3PARP1 | |
| SCHEMBL9383945 | 0.82 | HDAC3 (0.35) | HDAC3HSD17B3PARP1 | |
| SCHEMBL10703046 | 0.81 | HDAC3 (0.35) | HDAC3HSD17B3PARP1CA1CA2 | |
| SCHEMBL9380119 | 0.76 | HDAC3 (0.39) | HDAC3HSD17B3NOTUMKMT2ACA1 | |
| SCHEMBL28319875 | 0.75 | PDE3B (0.34) | — | |
| SCHEMBL3164408 | 0.75 | HDAC3 (0.35) | HDAC3PARP1KMT2A | |
| SCHEMBL3164410 | 0.75 | HDAC3 (0.35) | HDAC3PARP1KMT2A | |
| SCHEMBL8624431 | 0.73 | HDAC3 (0.51) | HDAC3HSD17B3PARP1 | |
| SCHEMBL28057297 | 0.73 | PTAFR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107921032-A | Inhibitors of VMAT2 for use in treating neurological diseases or disorders | 纽罗克里生物科学有限公司 | 2018-04-17 | — | — | CN | claimed |
| CN-106061506-A | Pharmaceutical compositions comprising an antipsychotic agent and a VMAT2 inhibitor and uses thereof | 纽罗克里生物科学有限公司 | 2016-10-26 | — | — | CN | claimed |
| JP-2011529031-A | — | — | 2011-12-01 | — | — | JP | claimed |
| EP-2318355-A1 | 1,1'-DIADAMANTYL CARBOXYLIC ACIDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | Boehringer Ingelheim International GmbH (DE) | 2011-05-11 | — | — | EP | claimed |
| WO-2010010174-A1 | 1,1'-DIADAMANTYL CARBOXYLIC ACIDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-28 | — | — | WO | claimed |
| WO-2024010784-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| CN-107303298-B | Pharmaceutical application of benzo [ g ] heteroaryl [ a, g ] quinolizine compound and preparation method thereof | 中国科学院上海药物研究所 | 2021-06-22 | — | — | CN | disclosed |
| CN-112996785-A | Therapeutic compounds | 希四克斯探索有限公司 | 2021-06-18 | — | — | CN | disclosed |
| CN-105431422-B | Isoindoline or isoquinoline compounds, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2019-08-30 | — | — | CN | disclosed |
| CN-110114071-A | Tricyclic compounds containing substituted pyridones and methods of using the same | 爱彼特生物制药公司 | 2019-08-09 | — | — | CN | disclosed |
| CN-105658238-B | For preventing and/or treating therapeutic agent used in hyperactivity dyskinesia | 索姆创新生物技术公司 | 2019-07-12 | — | — | CN | disclosed |
| CN-109456324-A | New isoindoline or isoquinoline compound, preparation method and the Pharmaceutical composition containing them | 法国施维雅药厂 | 2019-03-12 | — | — | CN | disclosed |
| US-20090170790-A1 | KETOLIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-07-02 | — | — | US | disclosed |
| EP-1807439-A2 | KETOLIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006099610-A2 | METHODS OF IDENTIFYING THERAPEUTIC TARGETS FOR THE TREATMENT OF VULVOVAGINAL ATROPHY | WYETH (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006046112-A2 | KETOLIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006046024-A1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| US-5512577-A | Bicyclic hexahydroaporphine and 1-benzyloctahydroisoquinoline therapeutic compositions and processes for utilizing said compositions | CREIGHTON UNIVERSITY (US) | 1996-04-30 | — | — | US | disclosed |
| EP-0303446-B1 | Pyrroloisoquinolines | MAY & BAKER LTD (GB) | 1994-05-25 | — | — | EP | disclosed |
| EP-0303446-A1 | Pyrroloisoquinolines | MAY & BAKER LIMITED (GB) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170790-A1 | KETOLIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | MGAM, HEXA, MGAM2 | HDAC3 308/4885HSD17B3 794/4885PARP1 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.